We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The Medicines and Healthcare products Regulatory Agency (MHRA) responses to freedom of information (FOI) requests for week commencing 10 October 2022.
The Medicines and Healthcare products Regulatory Agency (MHRA) responses to freedom of information (FOI) requests for week commencing 26 December 2022.
The Medicines and Healthcare products Regulatory Agency (MHRA) responses to freedom of information (FOI) requests for week commencing 7 November 2022.
The Medicines and Healthcare products Regulatory Agency (MHRA) responses to freedom of information (FOI) requests for week commencing 25 July 2022
The Medicines and Healthcare products Regulatory Agency (MHRA) responses to freedom of information (FOI) requests for week commencing 20 June 2022
The Medicines and Healthcare products Regulatory Agency (MHRA) responses to freedom of information (FOI) requests for week commencing 18 July 2022
The Medicines and Healthcare products Regulatory Agency (MHRA) responses to freedom of information (FOI) requests for week commencing 11 July 2022
The Medicines and Healthcare products Regulatory Agency (MHRA) responses to freedom of information (FOI) requests for week commencing 4 July 2022
Information on how the 2019 voluntary scheme for branded medicines pricing and access is controlling spend on branded medicines in the NHS.
These reports outline the MHRA’s Corporate and Business Plans, detailing the agency's strategic direction over the next three years.
Annual Report of the Human Medicines Regulations 2012 Advisory Bodies - the Commission on Human Medicines (CHM) and the British Pharmacopoeia Commission.
MHRA annual report and accounts 2022 to 2023.
UKHSA and Porton Biopharma Limited have committed to being more transparent with the public about when, how and why we use animals in research.
This People Strategy sets out the agency’s five core priorities over the next three years.
These equality objectives set out how the Medicines and Healthcare products Regulatory Agency (MHRA) will comply with the public sector equality duty.
Minutes of a meeting held between government, NHS England and the ABPI to review the operation of the 2019 voluntary scheme for branded medicines pricing and access.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).